More effective and less toxic than their predecessors, new cancer treatments have yet to complete the approval process due to a lack of trial volunteers. An estimation of less than three to five percent of cancer patients participate in the trials, mostly due to lack of awareness of their existence. Robert L Comis MD is president of the Coalition of National Cancer Cooperative Groups, a network of cancer clinical trial specialists. If we're stuck at three to four percent of adult patients participating in clinical trials, it will be years before these new treatments are not only tested but become available once we show that they're effective. Clinical trials of cancer drugs involve giving the patient the current best known treatment for a particular cancer, or giving cancer patients the opportunity to try a new one.
Patients receive leading-edge care during the studies.
The drugs have already been screened for safety. The fact is both of those things are totally incorrect. For cancer patients for whom other therapies have failed, participation in a clinical trial of a new therapy could offer renewed hope. Both are converted to other entities with important jobs to do. Studies show that both DHEA and melatonin are absorbed by skin when applied topically.